Publication | Closed Access

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Rheumatoid DisorderRheumatologyRheumatic DiseasesImmunologyPsoriatic ArthritisInflammatory Rheumatic DiseasePharmacotherapySafety AssessmentImmunotherapyMedicineRheumatoid ArthritisPilot Study